| Revvity Wins Permanent Injunction Enforcing Agreements with Cloud Software Group |
WALTHAM, Mass.--(BUSINESS WIRE)--Today, Revvity, Inc. (NYSE: RVTY) announced that the Massachusetts Superior Court has ruled in its favor and will issue a permanent injunction to enforce Revvity's rights under its agreements with Cloud Software Group (CSG) related to the Spotfire® software. This ruling follows a preliminary injunction issued in April 2024, which will become permanent, ensuring uninterrupted access to Spotfire software and support for Revvity and its customers, protecting operat. |
businesswire.com |
2025-02-20 14:30:00 |
Czytaj oryginał (ang.) |
| Revvity to Present at Upcoming Investor Conferences |
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced it will present at the following investor conferences in March 2025: 46th Annual Raymond James Institutional Investor Conference Monday, March 3, 2025 7:30 a.m. ET - Max Krakowiak, senior vice president and chief financial officer TD Cowen 45th Annual Health Care Conference Tuesday, March 4, 2025 9:10 a.m. ET - Prahlad Singh, president and chief executive officer Leerink Partners Global Healthcare Conference Tuesday, M. |
businesswire.com |
2025-02-20 10:00:00 |
Czytaj oryginał (ang.) |
| Molecular Infectious Disease Testing Market to Hit USD 17.78 Billion by 2029 with 13.7% CAGR | MarketsandMarkets™. |
DELRAY BEACH, Fla., Feb. 13, 2025 /PRNewswire/ -- The global Molecular Infectious Disease Testing market, valued at US$8.49 billion in 2023, is forecasted to grow at a robust CAGR of 13.7%, reaching US$9.37 billion in 2024 and an impressive US$17.78 billion by 2029. Major drivers of market growth include rising burden of infectious diseases and rapid technological advancements in molecular diagnostics. The increased incidence of emerging infectious diseases and antibiotic-resistant infections leads to greater demand for accurate and reliable diagnostics. In addition, there are rapid advances in the efficiency of molecular testing techniques, such as PCR and next-generation sequencing, which have improved diagnostic capabilities. These provide results that are more sensitive and at a faster speed, and allow for the simultaneous identification of multiple pathogens, which becomes vital in handling complex and continually changing infectious disease threats. These are some of the major contributors to the growing market. Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=40667482 Browse in-depth TOC on "Molecular Infectious Disease Testing Market" 539 - Tables61 - Figures448 - Pages An advancement in multiplex testing which could transform the molecular infectious disease testing market, is the integrated, fully automated multiplex diagnostic platforms. It will combine testing for multiple pathogens in a single reaction with the advantage of full automation, right from sample preparation to result interpretation. The automation of multiplex testing minimizes the chance of human error, enhances throughput, and accelerates the diagnostic process. These are the factors why this technology will thrive in environments of high demand such as hospitals, urgent care centers, and public health labs. The more these systems become user-friendly and affordable, the greater their potential will be to enhance access to multiplex tests in more rapid and comprehensive infectious disease surveillance and management across a range of healthcare settings. Based on product & service, the global molecular infectious disease testing market has been segmented into reagents & kits, instruments, and services & software. The fastest-growing segment within the molecular infectious disease testing market is the reagents and kits, mainly due to their critical role in making it possible for an accurate and efficient diagnosis. The growing use of molecular testing in clinical practices has caused the demand for good quality reagents and kits since they are indispensable in PCR, next-generation sequencing, and other molecular assays. The expansion of testing volumes within diagnostic laboratories and hospitals further propels the growth. Moreover, increased accessibility to ready-to-use, standardized kits and reagents that enhance sensitivity and reduce the turnaround time accelerate their demand in the molecular infectious disease testing market. Categorized by type, the molecular infectious disease testing market is segmented into single plex testing and multiplex testing. The multiplex testing segment is expected to witness the highest growth rate in the molecular infectious disease testing market because of its ability to test for more than one pathogen in a single test. Such capability can considerably reduce the testing time and cost while improving efficiency and accuracy of diagnostics. This is very helpful in complex infections, which could be due to multiple pathogens. The increasing demand for this type of testing in healthcare settings having high patient numbers is further due to the need for comprehensive, timely diagnostic solutions. Technological advancements in multiplex assay platforms have made this testing become indispensable in improving the clinical outcome, enhancing infection control measures. Key players in the molecular infectious disease testing market include Danaher (US), F. Hoffmann- La Roche Ltd (Switzerland), bioMérieux (France), Hologic, Inc. (US), Abbott (US), Thermo Fisher Scientific Inc. (US), QIAGEN (Netherlands), Revvity (US), Siemens Healthineers AG (Germany), BD (US), Grifols, S.A. (Spain), DiaSorin S.p.A. (Italy), and Seegene Inc. (South Korea). These companies have a diversified product portfolio and a good geographic presence also. With growing global burden of infectious diseases and increasing need for accurate diagnostics, such players are well-positioned to develop novel diagnostic technologies and further expand their offerings. They expand their market share through subsidiaries across the world based on the strength of their R&D capabilities and diversified product and services portfolios. Their product launches, agreements, acquisitions, and partnerships further enhance their portfolio while expanding the reach of their global business. Request Sample Pages : https://www.marketsandmarkets.com/requestsampleNew.asp?id=40667482 The key players operating in this market are Danaher (US), F. Hoffmann-La Roche Ltd (Switzerland), bioMérieux (France), Hologic, Inc. (US), Abbott (US), Thermo Fisher Scientific Inc. (US), QIAGEN (Netherlands), Revvity (US), Siemens Healthineers AG (Germany), BD (US), Grifols, S.A. (Spain), DiaSorin S.p.A. (Italy), and Seegene Inc. (South Korea). The market players have adopted several strategies such as advanced product development, partnerships, expansions, and acquisitions to strengthen their market position. The organic and inorganic strategies have allowed the market players to expand across geographies through the provision of advanced molecular infectious disease tests. Danaher emerged as the leader in the molecular infectious disease testing market in 2023. Its position as the leader in the market across the US serves as a platform from where it can penetrate more into the developing economies and build its global presence across more geographies. The company is also responsible for innovation in its products to cater to the varied needs of customers worldwide. This has assisted the company in building on its leadership position in the market. Additionally, the company also adopts certain organic growth strategies by launching new products and seeking relevant regulatory clearances. For example, in March 2024, the US FDA cleared the Xpert Xpress GBS test. In November 2022, it launched the Xpert Xpress MVP, a multiplexed PCR test. Such strategic steps have helped the company stay continuously in the lead in the molecular infectious disease testing market. F. Hoffmann-La Roche Ltd is a significant global player in the molecular infectious disease testing market. Its broad portfolio and presence in all parts of the world have helped it sustain its competitive advantage. Roche has a very good direct and indirect distribution network around the world, which enables it to balance out demand fluctuations in the different markets. Its strategic emphasis on organic as well as inorganic growth strategies makes the company stronger in the marketplace. For example, in September 2024, Roche launched the cobas Respiratory flex test. This is the first test by Roche using Roche's innovative and proprietary TAGS (Temperature-Activated Generation of Signal) technology. This technology identifies as many as 15 pathogens in a single PCR test by using multiplex polymerase chain reaction testing combined with color, temperature, and data processing. All these strategies, coupled with its strong presence in the market, have given Roche further opportunities to enhance its position within the molecular infectious disease testing market. bioMérieux is a prominent player in the molecular infectious disease testing market. Its robust position in the market is due to extensive distribution networks in America, Europe, the Middle East & Africa, and Asia Pacific. High investment in research & development, coupled with organic growth strategies, also helps bioMérieux strengthen its position in the market. Such initiatives include the launching of products and gaining appropriate regulatory approvals in order to extend its market shares. In December 2024, bioMérieux announced that the company's BIOFIRE FILMARRAY Tropical Fever (TF) Panel has achieved USD FDA Special 510(k) clearance. This new, innovative PCR-based testing solution brings fast and accurate pathogen identification in patients suffering from unexplained fever to clinicians, optimizing the treatment overall. For more information, Inquire Now! Related Reports: Molecular Diagnostics Market Veterinary Diagnostics Market Molecular Quality Controls Market IVD Contract Manufacturing Market Genetic Testing Market Get access to the latest updates on Molecular Infectious Disease Testing Companies and Molecular Infectious Disease Testing Market Size About MarketsandMarkets™: MarketsandMarkets™ has been recognized as one of America's best management consulting firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients. Earlier this year, we made a formal transformation into one of America's best management consulting firms as per a survey conducted by Forbes. The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry. To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook. Contact:Mr. Rohan SalgarkarMarketsandMarkets™ INC.1615 South Congress Ave.Suite 103, Delray Beach, FL 33445USA: +1-888-600-6441Email: [email protected]Visit Our Website: https://www.marketsandmarkets.com/ Logo: https://mma.prnewswire.com/media/1868219/MarketsandMarkets_Logo.jpg |
https://www.prnewswire.com |
2025-02-13 12:05:00 |
Czytaj oryginał (ang.) |
| RVTY Q4 Earnings Beat Estimates, Sales Miss, Segments Robust |
Revvity's fourth-quarter results showcase strong growth in Diagnostics business, along with recovery in Life Sciences segmental sales. |
zacks.com |
2025-01-31 16:15:24 |
Czytaj oryginał (ang.) |
| Revvity (RVTY) Reports Q4 Earnings: What Key Metrics Have to Say |
While the top- and bottom-line numbers for Revvity (RVTY) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. |
zacks.com |
2025-01-31 12:35:34 |
Czytaj oryginał (ang.) |
| Revvity, Inc. (RVTY) Q4 2024 Earnings Call Transcript |
Revvity, Inc. (NYSE:RVTY ) Q4 2024 Earnings Conference Call January 31, 2025 8:00 AM ET Company Participants Steve Willoughby - Senior Vice President, Investor Relations Prahlad Singh - President & Chief Executive Officer Max Krakowiak - Senior Vice President & Chief Financial Officer Conference Call Participants Doug Schenkel - Wolfe Research Vijay Kumar - Evercore ISI Patrick Donnelly - Citi Michael Ryskin - Bank of America Puneet Souda - Leerink Partners Matt Sykes - Goldman Sachs Luke Sergott - Barclays Andrew Cooper - Raymond James Catherine Schulte - Baird Dan Brennan - TD Cowen Operator Hello, everyone, and welcome to Revvity's Fourth Quarter 2024 Earnings Call. My name is Lydia, and I will be your operator today. |
seekingalpha.com |
2025-01-31 11:34:22 |
Czytaj oryginał (ang.) |
| Revvity (RVTY) Surpasses Q4 Earnings Estimates |
Revvity (RVTY) came out with quarterly earnings of $1.42 per share, beating the Zacks Consensus Estimate of $1.36 per share. This compares to earnings of $1.25 per share a year ago. |
zacks.com |
2025-01-31 10:11:26 |
Czytaj oryginał (ang.) |
| Revvity forecasts 2025 revenue, profit below estimates amid weak biotech spending |
Medical equipment maker Revvity forecast full-year profit and revenue for 2025 below Wall Street estimates on Friday, as it expects soft demand for its products and services used in drug research. |
reuters.com |
2025-01-31 09:32:50 |
Czytaj oryginał (ang.) |
| Revvity Announces Financial Results for the Fourth Quarter and Full Year of 2024 |
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) today reported financial results for the fourth quarter and full year ended December 29, 2024. Fourth Quarter 2024 The Company reported GAAP earnings per share of $0.78, as compared to $0.64 in the same period a year ago. GAAP revenue for the quarter was $729 million, as compared to $696 million in the same period a year ago. GAAP operating income from continuing operations for the quarter was $119 million, as compared to $77 million f. |
businesswire.com |
2025-01-31 08:00:00 |
Czytaj oryginał (ang.) |
| Revvity Gears Up for Q4 Earnings: What's in the Offing? |
RVTY's fourth-quarter results are likely to reflect decent performance in the Diagnostics segment. The Life Sciences segment is likely to have faced continued challenges in China. |
zacks.com |
2025-01-29 11:40:35 |
Czytaj oryginał (ang.) |
| Revvity (RVTY) Earnings Expected to Grow: Should You Buy? |
Revvity (RVTY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2025-01-24 13:06:11 |
Czytaj oryginał (ang.) |
| Will Revvity (RVTY) Beat Estimates Again in Its Next Earnings Report? |
Revvity (RVTY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report. |
zacks.com |
2025-01-23 15:16:36 |
Czytaj oryginał (ang.) |
| Revvity Ignites Scientific Breakthroughs at SLAS2025 |
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. is set to unveil its groundbreaking new Phenologic.AI™ software at SLAS2025 in San Diego, January 27-29. Designed to redefine cellular imaging workflows for Revvity's Harmony™ and Signals Image Artist™ software packages, the Phenologic.AI software leverages pre-trained deep-learning models to analyze brightfield images, providing an additional multiplexing channel and streamlined workflows for live cell analysis. This significant advancement expand. |
businesswire.com |
2025-01-23 10:00:00 |
Czytaj oryginał (ang.) |
| RVTY Stock Falls Despite FDA Nod for Automated Testosterone Test |
Revvity aims to expand the FDA-cleared menu for the EUROIMMUN family of ChLIA automation solutions to serve a wider patient pool. |
zacks.com |
2025-01-13 12:55:34 |
Czytaj oryginał (ang.) |
| Revvity to Hold Earnings Call on Friday, January 31, 2025; Provides Update on Financial Performance |
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced that it will release its fourth quarter and full year 2024 financial results prior to market open on Friday, January 31, 2025. The Company will host a conference call the same day at 8:00 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call. To access the call, a live audio webcast will be available via this reg. |
businesswire.com |
2025-01-12 19:00:00 |
Czytaj oryginał (ang.) |
| Here's Why You Should Retain Revvity Stock in Your Portfolio for Now |
RVTY's strong product portfolio raises optimism about the stock. |
zacks.com |
2024-12-31 11:45:40 |
Czytaj oryginał (ang.) |
| Revvity to Present at J.P. Morgan Healthcare Conference |
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) will present at the 43rd annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 8:15 a.m. PT in San Francisco, CA. President and Chief Executive Officer Prahlad Singh will provide an update on the Company and its strategic priorities. To access the presentation, a live audio webcast will be available via this page. A replay of the presentation will be posted on the Revvity Investor Relations website after the event and. |
businesswire.com |
2024-12-17 10:00:00 |
Czytaj oryginał (ang.) |
| Safe Biopharma: Revvity's Recurring Revenues And Diagnostics |
Revvity, Inc. is a leader in life sciences and diagnostics with diversified revenue streams and a strong balance sheet, making it a low-risk biopharma play. The company's recurring revenue base (80%) from consumables, services, and software ensures predictable income and financial stability. The company has a global footprint and an estimated TAM exceeding $60 billion, showcasing its significant market opportunity. |
seekingalpha.com |
2024-12-16 02:27:51 |
Czytaj oryginał (ang.) |
| Why Is Revvity (RVTY) Down 8.7% Since Last Earnings Report? |
Revvity (RVTY) reported earnings 30 days ago. What's next for the stock? |
zacks.com |
2024-12-04 14:36:36 |
Czytaj oryginał (ang.) |
| Revvity Broadens Relationship with Genomics England to Advance Genomics in the UK |
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced an expansion of its work with Genomics England that leverages both organizations' expertise and resources to advance critical genomic initiatives across the United Kingdom. Building on the parties' long and productive work history, this advanced collaboration is dedicated to accelerating Genomics England's renowned research programs, supporting diverse areas in genomics, and fostering talent in innovative healthcare fi. |
businesswire.com |
2024-11-20 10:00:00 |
Czytaj oryginał (ang.) |
| These Analysts Revise Their Forecasts On Revvity Following Q3 Results |
Revvity, Inc. RVTY reported better-than-expected third-quarter earnings on Monday. |
benzinga.com |
2024-11-05 16:06:14 |
Czytaj oryginał (ang.) |
| RVTY Q3 Earnings & Revenues Beat Estimates, Guidance Revised |
Revvity's third-quarter results showcase strong growth in Diagnostics business, along with a decline in Life Sciences segmental sales. |
zacks.com |
2024-11-04 15:40:18 |
Czytaj oryginał (ang.) |
| Revitty (RVTY) Q3 2024 Earnings Call Transcript |
Revitty Incorporated (NYSE:RVTY ) Q3 2024 Earnings Conference Call November 4, 2024 8:00 AM ET Company Participants Prahlad Singh - President, Chief Executive Officer Max Krakowiak - Senior Vice President, Chief Financial Officer Steve Willoughby - Head of Investor Relations Conference Call Participants Mike Ryskin - Bank of America Vijay Kumar - Evercore ISI Dan Leonard - UBS Andrew Cooper - Raymond James Luke Sergott - Barclays Dan Brennan - TD Cowen Puneet Souda - Leerink Partners Dan Arias - Stifel Matt Sykes - Goldman Sachs Brandon Couillard - Wells Fargo Patrick Donnelly - Citi Jack Meehan - Nephron Research Operator Hello everyone and welcome to Revitty's third quarter 2024 earnings conference call. My name is Lydia and I will be your Operator today. |
seekingalpha.com |
2024-11-04 14:30:29 |
Czytaj oryginał (ang.) |
| Here's What Key Metrics Tell Us About Revvity (RVTY) Q3 Earnings |
Although the revenue and EPS for Revvity (RVTY) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. |
zacks.com |
2024-11-04 12:35:32 |
Czytaj oryginał (ang.) |
| Revvity (RVTY) Surpasses Q3 Earnings and Revenue Estimates |
Revvity (RVTY) came out with quarterly earnings of $1.28 per share, beating the Zacks Consensus Estimate of $1.13 per share. This compares to earnings of $1.18 per share a year ago. |
zacks.com |
2024-11-04 10:11:23 |
Czytaj oryginał (ang.) |
| Revvity cuts 2024 revenue forecast amid biotech spending slowdown |
Revvity cut its 2024 revenue forecast as reduced biotech spending and a strong dollar weigh on demand for its tools and services used in drug development. |
reuters.com |
2024-11-04 09:55:26 |
Czytaj oryginał (ang.) |
| Revvity Announces Financial Results for the Third Quarter of 2024 |
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today reported financial results for the third quarter ended September 29, 2024. The Company reported GAAP earnings per share of $0.77, as compared to $0.08 in the same period a year ago. GAAP revenue for the quarter was $684 million, as compared to $671 million in the same period a year ago. GAAP operating income from continuing operations for the quarter was $98 million, as compared to $69 million for the same period a year ago. GAA. |
businesswire.com |
2024-11-04 08:00:00 |
Czytaj oryginał (ang.) |
| Revvity to Report Q3 Earnings: What's in Store for the Stock? |
RVTY third-quarter results are likely to reflect decent performance in the Diagnostics segment, while the Life Sciences segment is likely to face continued challenges in China. |
zacks.com |
2024-11-01 16:16:10 |
Czytaj oryginał (ang.) |
| Earnings Preview: Revvity (RVTY) Q3 Earnings Expected to Decline |
Revvity (RVTY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2024-10-28 13:05:23 |
Czytaj oryginał (ang.) |
| Revvity Board Declares Quarterly Dividend |
WALTHAM, Mass.--(BUSINESS WIRE)--The Board of Directors of Revvity, Inc. (NYSE: RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on February 7, 2025 to all shareholders of record at the close of business on January 17, 2025. About Revvity At Revvity, “impossible” is inspiration, and “can't be done” is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows fro. |
businesswire.com |
2024-10-24 20:05:00 |
Czytaj oryginał (ang.) |
| Revvity Shares Decline Despite Launch of Transcribe AI Solution |
RVTY introduces Transcribe AI that digitizes handwritten test request forms, improving workflow speed and reducing manual data entry errors. |
zacks.com |
2024-10-23 15:51:07 |
Czytaj oryginał (ang.) |
| Revvity Highlights its Strong Progress on Sustainability and Workplace Culture in 2024 Impact Report |
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) today unveils its annual Impact Report, a declaration of the Company's sustainability, social and governance strategy, initiatives and performance. The report showcases Revvity's continued evolution and strengthened commitments to creating a lasting, positive impact on the world. “Whether it's from developing groundbreaking solutions that drive positive health outcomes or through our sustainability initiatives, such as reducing waste a. |
businesswire.com |
2024-10-22 12:00:00 |
Czytaj oryginał (ang.) |
| RVTY's Latest Launch to Enable APOE Genotyping of Alzheimer's Disease |
Revvity's latest solution for specific typing of AD-associated APOE gene is likely to allow assessment of a patient's risk for adverse effects from new anti-amyloid therapy for Alzheimer's. |
zacks.com |
2024-10-10 15:00:41 |
Czytaj oryginał (ang.) |
| Here's Why You Should Retain Revvity Stock in Your Portfolio for Now |
RVTY's continued focus on innovations and a strong product portfolio raise optimism about the stock. |
zacks.com |
2024-10-07 16:35:33 |
Czytaj oryginał (ang.) |
| Reasons to Retain Revvity Stock in Your Portfolio for Now |
RVTY's strong product portfolio raises optimism about the stock. |
zacks.com |
2024-09-06 14:01:26 |
Czytaj oryginał (ang.) |